SLS Venture

SLS Venture (Scandinavian Life Science Venture) was a prominent venture capital firm based in Stockholm, Sweden, dedicated to the life sciences sector. Founded in 1999, the firm focused on early- to mid-stage investments in biotechnology, pharmaceuticals, and medical technology companies, primarily within the Nordic region. It managed several funds, including the SLS Venture Fund and the Scandinavian Life Science Venture II, with a total capital base that made it one of the largest specialized life science investors in Northern Europe. The firm played a crucial role in the growth of numerous startups, leading to significant exits such as the acquisition of Biolipox by Orexo and the IPO of Aerocrine. While the firm is no longer actively making new investments, its legacy remains significant in the European biotech ecosystem.